Mitchell Keegan
Keine laufenden Positionen mehr
Profil
Mitchell Keegan worked as a Senior Director-Drug Development at Gloucester Pharmaceuticals, Inc. from 2008 to 2008.
Prior to that, he was a Pharmacology Director at CombinatoRx, Inc. from 2001 to 2005 and a Study Director at Toxikon Corp.
in 2001.
From 2008 to 2011, he worked as a Vice President-Drug Development at Curis, Inc. Keegan received his undergraduate degree from The University of Sydney and his doctorate from the University of Western Sydney.
Ehemalige bekannte Positionen von Mitchell Keegan
| Unternehmen | Position | Ende |
|---|---|---|
| CURIS, INC. | Corporate Officer/Principal | 15.10.2011 |
Gloucester Pharmaceuticals, Inc.
 Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Corporate Officer/Principal | 01.03.2008 |
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Corporate Officer/Principal | 01.04.2005 |
Toxikon Corp.
 Toxikon Corp. Miscellaneous Commercial ServicesCommercial Services Toxikon Corp. provides life science and laboratory services. The firm's services include toxicology, chronic, reproductive and chronic toxicity, genetic toxicology, carcinogenicity, pharmacokinetics, toxicokinetics, and microbiology. It offers services to the pharmaceutical, medical devices, and drug companies. The company was founded in 1977 and is located in Bedford, MA. | Corporate Officer/Principal | 01.12.2001 |
Ausbildung von Mitchell Keegan
| University of Western Sydney | Doctorate Degree |
| The University of Sydney | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Health Technology |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Toxikon Corp.
Toxikon Corp. Miscellaneous Commercial ServicesCommercial Services Toxikon Corp. provides life science and laboratory services. The firm's services include toxicology, chronic, reproductive and chronic toxicity, genetic toxicology, carcinogenicity, pharmacokinetics, toxicokinetics, and microbiology. It offers services to the pharmaceutical, medical devices, and drug companies. The company was founded in 1977 and is located in Bedford, MA. | Commercial Services |
